FierceBiotech to temporarily relocate to Boston for #BIO2012

Arsalan Arif, Publisher
Follow me on Twitter and LinkedIn

Well, the logistics sure feel like we're temporarily relocating the Fierce Life Sciences team to Boston next week. There's fifteen of us around for BIO's 2012 International Convention and we're eager to hear firsthand from you, our readers, on how you use FierceBiotech. Readers are our best source of good ideas so keep them coming.

We'll have a dedicated page for all #BIO2012 content once the convention kicks off. Twitter offers readers the best way to see real-time coverage. This twitter list has all Fierce staffers on-site, or you can follow us individually here:

John Carroll - Editor-in-chief, @JohnCFierce
Ryan McBride - Executive Editor, @RyanMFierce
Tracy Staton - Senior Editor, @FiercePharma
Eric Palmer - Senior Editor, @EricPFierce
Mark Hollmer - Editor-at-Large, @MarkHFierce
Suzanne Elvidge - Editor, @Suzannewriter
Damian Garde - Associate Editor, @DamianFierce
Nesa Nourhohammadi - Associate Editor, @NesaNFierce
Jennifer Levin - Assistant Editor, @JenniferFierce
Rebecca Friend - Associate Publisher, @RebeccaEFriend
Arsalan Arif - Publisher @ArsalanFierce

We're taking meetings, wandering the exhibition floor, and always eager to chat. Come find us! And have a great weekend.

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.